-+ 0.00%
-+ 0.00%
-+ 0.00%
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
Share
Listen to the news

First Patient Dosed with JOTROL™ Marks Major Clinical Milestone for Jupiter Neurosciences’
Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL™ in Patients with Parkinson’s Disease

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending